Published April 1, 2014 | Version v1
Journal article

Outcomes and Toxicity for Hypofractionated and Single-Fraction Image-Guided Stereotactic Radiosurgery for Sarcomas Metastasizing to the Spine

  • 1. Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York (United States)
  • 2. Department of Neurosurgery, Memorial Sloan-Kettering Cancer Center, New York, New York (United States)
  • 3. Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, New York (United States)
  • 4. Department of Medical Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York (United States)

Description

Purpose: Conventional radiation treatment (20-40 Gy in 5-20 fractions, 2-5 Gy per fraction) for sarcoma metastatic to the spine provides subtherapeutic doses, resulting in poor durable local control (LC) (50%-77% at 1 year). Hypofractionated (HF) and/or single-fraction (SF) image-guided stereotactic radiosurgery (IG-SRS) may provide a more effective means of managing these lesions. Methods and Materials: Patients with pathologically proven high-grade sarcoma metastatic to the spine treated with HF and SF IG-SRS were included. LC and overall survival (OS) were analyzed by the use of Kaplan-Meier statistics. Univariate and multivariate analyses were performed by the use of Cox regression with competing-risks analysis; all confidence intervals are 95%. Toxicities were assessed according to Common Terminology Criteria for Adverse Events, version 4.0. Results: From May 2005 to November 11, 2012, 88 patients with 120 discrete metastases received HF (3-6 fractions; median dose, 28.5 Gy; n=52, 43.3%) or SF IG-SRS (median dose, 24 Gy; n=68, 56.7%). The median follow-up time was 12.3 months. At 12 months, LC was 87.9% (confidence interval [CI], 81.3%-94.5%), OS was 60.6% (CI, 49.6%-71.6%), and median survival was 16.9 months. SF IG-SRS demonstrated superior LC to HF IG-SRS (12-month LC of 90.8% [CI, 83%-98.6%] vs 84.1% [CI, 72.9%-95.3%] P=.007) and retained significance on multivariate analysis (P=.030, hazard ratio 0.345; CI, 0.132-0.901]. Treatment was well tolerated, with 1% acute grade 3 toxicity, 4.5% chronic grade 3 toxicity, and no grade >3 toxicities. Conclusions: In the largest series of metastatic sarcoma to the spine to date, IG-SRS provides excellent LC in the setting of an aggressive disease with low radiation sensitivity and poor prognosis. Single-fraction IG-SRS is associated with the highest rates of LC with minimal toxicity

Availability note (English)

Available from http://dx.doi.org/10.1016/j.ijrobp.2013.12.042

Additional details

Identifiers

DOI
10.1016/j.ijrobp.2013.12.042;
PII
S0360-3016(13)03720-6;

Publishing Information

Journal Title
International Journal of Radiation Oncology, Biology and Physics
Journal Volume
88
Journal Issue
5
Journal Page Range
p. 1085-1091
ISSN
0360-3016
CODEN
IOBPD3

INIS

Country of Publication
United States
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
46122414
Subject category
S62: RADIOLOGY AND NUCLEAR MEDICINE;
Descriptors DEI
HAZARDS; METASTASES; MULTIVARIATE ANALYSIS; PATIENTS; RADIATION DOSES; RADIOSENSITIVITY; RADIOTHERAPY; RISK ASSESSMENT; SARCOMAS; SURGERY; TOXICITY; VERTEBRAE
Descriptors DEC
BODY; DISEASES; DOSES; MATHEMATICS; MEDICINE; NEOPLASMS; NUCLEAR MEDICINE; ORGANS; RADIOLOGY; SENSITIVITY; SKELETON; STATISTICS; THERAPY

Optional Information

Copyright
Copyright (c) 2014 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.